BioMarin Pharmaceutical Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-117.0M | $-630.2M | $-171.8M | $-134.0M | $-176.4M | $-114.3M | $-53.8M | $205.8M |
| Depreciation & Amortization | $87.9M | $96.9M | $47.2M | $45.9M | $36.0M | $44.3M | $35.0M | $27.7M |
| Depreciation | $75.8M | $73.2M | $50.1M | $44.3M | $36.5M | $34.9M | $31.9M | $23.3M |
| Amortization | — | — | — | $10.5M | — | $6.8M | $500.0K | — |
| Stock-Based Compensation | $140.3M | $134.6M | $111.5M | $86.4M | $64.4M | $47.3M | $43.9M | $38.4M |
| Net Cash from Operating Activities | $-8.8M | $-227.8M | $-219.5M | $-70.4M | $-59.6M | $17.6M | $18.4M | $18.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $199.2M | $148.4M | $227.7M | $117.1M | $65.2M | $44.6M | $73.2M | $49.5M |
| Business Acquisitions | $0 | $2.8M | $538.4M | $0 | $9.9M | $0 | $0 | $33.0M |
| Net Cash from Investing Activities | $-305.5M | $-484.0M | — | — | $-298.8M | $-195.6M | $-89.6M | $-101.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $507.1M | $727.1M | — | — | $746.7M | $312.3M | $29.3M | $3.5M |
| Net Change in Cash | $189.7M | $11.3M | $-478.4M | $306.7M | $388.3M | $134.3M | $-41.8M | $-79.1M |
| Free Cash Flow | $-208.0M | $-376.2M | $-447.2M | $-187.5M | $-124.8M | $-27.0M | $-54.8M | $-30.7M |